Qyuns Therapeutics (SEHK:2509) Stock Turns Profitable While Forecasts Cloud The Outlook

Qyuns Therapeutics came into this earnings print with a profitable twelve month track record and a stock that has drifted, with the share price down about 6.6% over the past week but still modestly higher over three months. The headline this half is simple: the company delivered H1 2026 revenue of C¥424.1m and net income of C¥203.3m, which keeps the recent profitability story intact.

The tension for you as an investor sits between those solid trailing numbers and a stock valued at roughly 5.9x trailing P/E, while consensus still points to a very steep earnings decline over the coming years.

Is Qyuns Therapeutics trading at a genuine bargain on a 5.9x trailing P/E, or does the steep earnings decline forecast justify the discount? Compare the current share price to detailed cash flow and peer assumptions in our valuation analysis for Qyuns Therapeutics

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): C¥424.1m vs. C¥206.5m (up about 105%)
• Net Income, Excluding Extra Items (H1 2026 vs. H1 2025): C¥203.3m profit vs. a loss of C¥28.3m (moved from loss to profit)
• Basic EPS, Earnings Per Share (H1 2026 vs. H1 2025): C¥0.91 vs. a loss per share of C¥0.13 (moved from loss to profit)
• Trailing Twelve Month Net Income, Excluding Extra Items (TTM to H1 2026 vs. TTM to H1 2025): C¥546.1m vs. a loss of C¥191.8m (moved from loss to profit over the year)

Prefer clean visuals instead of another wall of earnings tables and figures? See Qyuns Therapeutics' full financial picture with an at-a-glance view of its recent profitability story in the company report for Qyuns Therapeutics.

Qyuns Therapeutics: Earnings Power Supporting Optimists

For investors leaning positive on Qyuns Therapeutics, the latest earnings give some support. Revenue for H1 2026 is C¥424.1m, roughly double the prior period, and net income has moved from a loss to a C¥203.3m profit. On a trailing basis, the shift from a C¥191.8m loss to a C¥546.1m profit suggests the business is currently funding itself. That can matter for a clinical heavy story where investors often worry most about persistent cash burn.

Qyuns Therapeutics: Risks That Still Temper Enthusiasm

The recent move into profit does not remove the typical biotech risks that follow Qyuns Therapeutics. The company remains closely tied to clinical and regulatory outcomes for its immune and dermatology pipeline. The share price is down about 6.6% over seven days even after these results, which indicates lingering caution. Investors may still be weighing trial and funding risk against the new earnings base, rather than treating the latest numbers as a decisive turning point.

Compare Qyuns Therapeutics' new profit base and the recent HK$16.78 share price move with what the Street is actually baking in. See the consensus price target analysis for Qyuns Therapeutics to check whether analysts think the current valuation lines up with their targets.

Stay Ahead With Qyuns Therapeutics

If Qyuns Therapeutics looks interesting after its move from losses to profit and a 5.9x trailing P/E, register for free with Simply Wall St and add it to a Watchlist to monitor the share price against fair value and watch for a better entry point. Once you own it or any other stock, keep on top of what really matters using the Portfolio Command Center so you only see the most important updates on your holdings. For a longer term view, compare your thinking with thousands of other investors through the Community and see how sentiment around Qyuns Therapeutics is evolving. By spotting potential catalysts and risks early, you put yourself in a better position to act before the wider market catches up.

Seeking Alternatives Beyond Qyuns Therapeutics?

Fresh stock ideas can move from quiet to breakout faster than most investors react. Scan curated opportunities while they are still under the radar for now and act now.

• Spot potential breakout compounding stories early by scanning a curated 610 high quality undiscovered gems before momentum traders catch on and pricing power starts slipping away.
• Strengthen your portfolio backbone by zeroing in on a hand picked list of solid balance sheet and fundamentals stocks (434 results) while balance sheets and fundamentals are still priced as if nothing has changed yet.
• Lock in potential income ideas by reviewing a filtered set of 434 dividend fortresses while yields and payout strength remain available to early movers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com